Vaccine最新文献

{"title":"Corrigendum to \"Social processes, practical issues, and COVID-19 vaccination among hesitant adults\" [Vaccine 41(35) (2023) 5150-5158].","authors":"Don E Willis, Sharon Reece, Morgan Gurel-Headley, James P Selig, Ji Li, Stacy Zimmerman, Lawrence E Cornett, Pearl A McElfish","doi":"10.1016/j.vaccine.2025.127583","DOIUrl":"10.1016/j.vaccine.2025.127583","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"62 ","pages":"127583"},"PeriodicalIF":3.5,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omicron JN.1 escape neutralization by omicron subvariants infection in elderly individuals.","authors":"Fan Liu, Yuanling Yu, Jincheng Tong, Jiajing Wu, Qiong Lu, Ruixin Liu, LinLin Cao, Xiaolu Ma, Jihong Zhu, Tianbing Wang, Shuo Liu, Ziteng Liang, Xuelian Wu, Tao Li, Chenyan Zhao, Jianhui Nie, Youchun Wang, Weijin Huang, Weibo Gao","doi":"10.1016/j.vaccine.2024.126658","DOIUrl":"10.1016/j.vaccine.2024.126658","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126658"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Effect of vaccine education intervention on vaccine uptake and vaccine knowledge among older adults: A systematic review with meta-analysis\" [Vaccine 56 (2025) 127182].","authors":"Yee Tang Chan, Sek Ying Chair, Rui Tong Gao, Ming Him Ng, Vivian Wing Yan Lee","doi":"10.1016/j.vaccine.2025.127570","DOIUrl":"10.1016/j.vaccine.2025.127570","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127570"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells\" [Vaccine 21(17-18) (2003) 1989-1994].","authors":"Motoharu Abe, Syoji Kuzuhara, Yoichiro Kino","doi":"10.1016/j.vaccine.2025.127426","DOIUrl":"10.1016/j.vaccine.2025.127426","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127426"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral vaccination with live Mycoplasma pneumoniae elicits a respiratory protective immunity in a murine model.","authors":"Lan Yu, Chunyan Chen, Guiting He, Yan Meng, Huanbing Long, Jiarong He, Shuihong Li, Cuiming Zhu","doi":"10.1016/j.vaccine.2025.127460","DOIUrl":"10.1016/j.vaccine.2025.127460","url":null,"abstract":"<p><p>Vaccine development targeting Mycoplasma pneumoniae began in the 1960s, but achieving safe and effective immunization is still challenging. Careful consideration of the immunization pathway is one of the critical aspects of vaccine development. In this investigation, C57BL/6 J mice were intragastrically vaccinated with live M. pneumoniae, and the short-term safety and resultant immune effects were evaluated. Oral administration likely demonstrated intestinal clearance with restricted systemic dissemination and no tissue pathogenicity in both the intestinal and pulmonary tracts. Furthermore, the oral vaccination with live M. pneumoniae effectively reduced the pathogen burden in the lung, alleviated pulmonary inflammation, and reduced the pulmonary secretion of IL-1β and TNF-α after intranasal bacterial infection 3 or 15 weeks after the last dose. Moreover, Airway exposure to M. pneumoniae in live pathogen intragastric vaccinated mice triggered robust recall responses, marked by the elevation of systemic mycoplasma-specific IgG and IgM, alongside pulmonary mucosal IgA, paralleled by clonal expansion of Th1, Th2, and CTL. In conclusion, oral delivery presents a promising route for developing M. pneumoniae vaccines.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127460"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201.","authors":"Anna R Giuliano, Anna Beltrame, Luisa L Villa, Eduardo Lazcano-Ponce, Jorge Santana-Bagur, Betania Allen-Leigh, Alejandra J Portillo-Romero, Vikrant V Sahasrabuddhe, Margaret G House, Emma Brofsky, Lenice Galan de Paula, Roberto Carvalho da Silva, Michael J Schell, Julie Rathwell, Kimberly Isaacs-Soriano, Wenyi Fan, Caique Mello, Grant B Ellsworth, Timothy Wilkin","doi":"10.1016/j.vaccine.2025.127447","DOIUrl":"10.1016/j.vaccine.2025.127447","url":null,"abstract":"<p><p>HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has increased significantly among men, especially among men living with HIV. HPV vaccines have proven efficacy in preventing persistent anogenital HPV infections. However, less is known regarding vaccine efficacy against persistent oral HPV infection, the obligate precursor of OPSCC. In 2020, the 9-valent HPV (9vHPV) vaccine received accelerated approval from the FDA for the indication of prevention of HPV-related OPSCC and other head and neck cancers, pending confirmation of clinical benefit in further trials. Currently a Phase III trial is ongoing to evaluate efficacy of the 9vHPV vaccine in preventing persistent oral HPV infection in immunocompetent men (NCT04199689); however, no trials have been conducted in people living with HIV. Here we describe the rationale, design, and study population characteristics of the first randomized (1:1), double-blind, placebo-controlled trial evaluating the efficacy and immunogenicity of the 9vHPV vaccine in preventing persistent oral HPV infection in men aged 20-50 living with HIV. The primary objective is to demonstrate that the 9vHPV vaccine when given in a 3-dose regimen (Day 1, Months 2 and 6) reduces the incidence of persistent (≥6 months) oral HPV infection with 9vHPV vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in men living with HIV who are oral HPV negative to the relevant HPV type at enrollment, compared with placebo. The trial began in February 2021 and completed enrollment of 700 men at clinical sites in Brazil, Mexico, and Puerto Rico in February 2024. The secondary objectives are to evaluate the vaccine-induced serum anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 responses, and the safety and tolerability of the 9vHPV vaccine in men living with HIV. Results from this study may inform policy regarding vaccination strategies for people living with HIV. ClinicalTrials.gov Identifier: NCT04255849.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127447"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under five years of age in the 13-valent pneumococcal conjugate vaccine era in Tanzania. A short communication.","authors":"James Samwel Ngocho, Christa E van der Gaast-de Jongh, Julieth Sebba, Monica Mtei, Grace Kinabo, Blandina T Mmbaga, Marien I de Jonge","doi":"10.1016/j.vaccine.2025.127336","DOIUrl":"10.1016/j.vaccine.2025.127336","url":null,"abstract":"<p><p>To determine the impact of pneumococcal vaccination on nasopharyngeal carriage in Tanzania, we assessed the serotype distribution of S. pneumoniae isolated from nasopharyngeal swab samples. These samples were collected in 539 children below the age of 5 years in two cross-sectional studies, one before and one after PCV13 rollout. In the second study, post-PCV13 rollout, only children who completed the PCV13 vaccination schedule, were included. From the study conducted before the introduction of PCV13, 61 (55 %) of S. pneumoniae serotypes were vaccine types, compared to 89 (23.3 %) post-PCV13. The most common serotypes in the pre-PCV13 period were 19F (n = 23, 20.7 %) and 6B (n = 11, 9.9 %). In the post-PCV13 era, serotypes 15B/C (n = 40, 10.5 %), and 3 (n = 29, 7.6 %) were most prevalent. We observed the emergence of 14 non-vaccine serotypes not detected in the pre-vaccine era. Further surveillance is needed to assess shifts in carriage and their implications for the protection against invasive pneumococcal disease.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127336"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12780951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Emergence of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under the age of five years in the 13-valent pneumococcal conjugate vaccine era in Tanzania. A short communication\" [Vaccine 48 (2025) 126724].","authors":"James Samwel Ngocho, Christa E van der Gaast de Jongh, Julieth Sebba, Monica Mtei, Grace Kinabo, Blandina T Mmbaga, Marien I de Jonge","doi":"10.1016/j.vaccine.2025.127335","DOIUrl":"10.1016/j.vaccine.2025.127335","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127335"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue vaccination and outbreaks: Bridging clinical diagnosis with genomic surveillance.","authors":"Marta Giovanetti, Eleonora Cella, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Svetoslav Nanev Slavov","doi":"10.1016/j.vaccine.2025.126755","DOIUrl":"10.1016/j.vaccine.2025.126755","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126755"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric virus-like particles replacing the loop on the surface of VP60 from rabbit hemorrhagic disease virus (RHDV) provide protection against two serotypes of RHDV.","authors":"Wangzhen Xiang, Beibei Pan, Yuxin Hao, Fei Wang, Jialu Bao, Shanchun Su, Shuai Qie, Chungang Pan, Zhen Cao, Xinyue Liu, Jiajun Wu, Tong Zhang, Xinyan Zhai, Fei Yang, Peng Qi, Jiangtao Wang, Jin Xiao, Xin Guo","doi":"10.1016/j.vaccine.2025.127427","DOIUrl":"10.1016/j.vaccine.2025.127427","url":null,"abstract":"<p><p>In recent years, the rabbit hemorrhagic disease virus 2(RHDV GI.2) has rapidly spread worldwide due to its broad natural host range, strong pathogenicity, and significant antigenic differences from the traditional RHDV1 (GI.1). The widespread prevalence of both GI.1 and GI.2 RHDV poses a serious threat to the healthy development of the global rabbit industry. Despite this, there is still a notable absence of effective multivalent or broad-spectrum vaccines for controlling RHD(GI.1 and GI.2). In the present study, we developed a broad-spectrum chimeric antigen vaccine using a substitution strategy targeting the surface loop of the main antigen protein VP60 of RHDV. The chimeric VP60 antigen, expressed by a recombinant baculovirus expression system, was successfully assembled into virus-like particles (VLPs). The VLPs exhibited typical natural virus size and morphology under an electron microscope. Immunization with chimeric VLPs effectively protected rabbits from lethal challenged by both virulent strains of RHDV, GI.1 and GI.2, showing an effect comparable to that of a mixture vaccine containing two wild-type VLPs. These findings demonstrate a promising strategy for developing a cost-effective and straightforward preparation process for broad-spectrum vaccine against RHD.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127427"},"PeriodicalIF":3.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}